Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2527379 | Clinical Therapeutics | 2012 | 23 Pages |
Abstract
GA reduced relapses and clinical progression compared with placebo or standard treatment and clinical progression compared with IFNs. Serious adverse events were comparable in GA and IFNs. The BR assessments that were based on these data found that the clinical benefits of GA outweigh the risks, although results differ, depending on the quantitative BR model used, and are limited by the absence of reliable data for assigning weights to the model.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Nawab MD, DPhil (Oxon), Ignacio VMD, MPH, Rainel MD, PhD,